Latest Breaking News On - Davidn cade - Page 2 : comparemela.com

Telix Announces Positive rPFS Data from ProstACT SELECT

Telix Announces Positive rPFS Data from ProstACT SELECT
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesNat lenzoDavidn cadeLisa wilsonKyahn williamsonTelix pharmaceuticals limited disclosure committeeAustralian securities exchangeHealth canadaCorporate communicationsDrug administrationTelix pharmaceuticals limitedTelix pharmaceuticalsSite communicationsAustralian therapeutic goods administrationNuclear oncologistPharmaceuticals limited

Telix (ASX:TLX) Advances in Prostate Cancer Treatment

Telix Pharmaceuticals (ASX: TLX) has completed the CUPID study, a Phase I trial on its investigational drug TLX592 for prostate cancer patients

Davidn cadeTelix pharmaceuticalsSonic healthcare

Telix Completes Proof-of-Concept Study of TLX592 Targeted

Telix Completes Proof-of-Concept Study of TLX592 Targeted
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesKyahn williamsonDavidn cadeCorporate communicationsDrug administrationHealth canadaAustralian therapeutic goods administrationTelix pharmaceuticals limitedTelix pharmaceuticalsTelix pharmaceuticals limited disclosure committeeAustralian securities exchangePharmaceuticals limitedPositron emission tomographyGroup chief medical officer

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesKyahn williamsonDavidn cadeTelix pharmaceuticals limitedAustralian securities exchangeTelix pharmaceuticals limited disclosure committeeTelix pharmaceuticalsDrug administrationCorporate communicationsHealth canadaAustralian therapeutic goods administrationCompletes proof of concept studyAlpha therapyPharmaceuticals limitedPositron emission tomographyGroup chief medical officer

Telix Pharmaceuticals Limited: Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.Establishes proof-of-concept for Telix's proprietary

United statesDavidn cadeKyahn williamsonTelix pharmaceuticals limitedCorporate communicationsTelix pharmaceuticals limited disclosure committeeHealth canadaAustralian therapeutic goods administrationAustralian securities exchangeTelix pharmaceuticalsDrug administrationPrnewswire telix pharmaceuticals limitedPharmaceuticals limitedPositron emission tomographyGroup chief medical officerIhr portfolio